The core focus of pHion Therapeutics is the internal development of a pipeline of therapeutic and prophylactic mRNA vaccines.

Due to the wide applicability of the company’s stealth-like delivery platform, pHion is also looking to engage in complementary partnering with pharma and biotech companies and to license out its delivery technology.

The company is specifically looking to partner PTX-C1 for pancreatic cancer that delivers the active metabolite of gemcitabine which overcomes current issues with resistance.